Healthy high growth potential

Results

1476

Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.

1476 companies

CompanyLast Price7D Return1Y ReturnMarket CapAnalysts TargetValuationGrowthDiv YieldIndustry
325
HK$41.56-4.6%-70.6%HK$10.3bHK$81.0014.122.7%n/aConsumer Durables
2480
HK$12.810.08%-47.0%HK$2.5bHK$31.003.377.1%n/aPharmaceuticals & Biotech
1729
HK$16.92-12.7%128.0%HK$37.8bHK$25.0048.233.6%0.3%Capital Goods
1357
HK$3.75-6.9%-58.5%HK$17.1bHK$9.3220.231.4%2.7%Media
1860
HK$10.13-12.7%42.7%HK$15.6bHK$18.2626.641.1%n/aMedia
2315
HK$46.7412.6%107.7%HK$47.6bHK$62.0262.340.4%n/aPharmaceuticals & Biotech
6990
HK$436.209.6%33.3%HK$101.7bHK$547.6442.844.8%n/aPharmaceuticals & Biotech
2171
HK$14.26-9.5%-38.3%HK$8.5bHK$21.1458.480.6%n/aPharmaceuticals & Biotech
3881
HK$20.32-11.6%n/aHK$8.9bn/a8.7107.6%n/aCapital Goods
3636
HK$15.30-1.4%n/aHK$2.3bHK$31.206.140.2%2.5%Materials
FWRY
ج.م18.40-2.4%52.7%ج.م62.7bج.م22.4523.627.3%n/aDiversified Financials
MDGL
US$536.954.6%78.9%US$12.2bUS$678.7110.959.2%n/aPharmaceuticals & Biotech
CORT
US$86.958.9%25.5%US$9.4bUS$88.00200.048.9%n/aPharmaceuticals & Biotech
AXSM
US$244.771.2%137.7%US$12.4bUS$276.4717.857.4%n/aPharmaceuticals & Biotech
LITE
US$858.063.6%837.9%US$66.2bUS$1,111.29152.179.1%n/aTech
CRDO
US$271.95-0.02%210.5%US$45.8bUS$269.81107.427.5%n/aSemiconductors
NVDA
US$200.090.03%30.5%US$4.7tUS$301.6230.422.2%0.5%Semiconductors
688072
CN¥832.001.5%454.7%CN¥234.1bCN¥511.08142.435.2%0.04%Semiconductors
MOD
US$267.02-3.8%172.5%US$13.5bUS$340.86116.149.3%n/aCapital Goods
543273
₹2,183.55-6.1%172.7%₹53.4b₹2,500.0067.753.9%n/aTransportation
A458870
₩39,850.0017.6%350.3%₩1.5t₩69,000.0049.941.5%n/aHealthcare
MONOLITH
₹764.852.5%139.8%₹16.6b₹960.0072.237.2%n/aMaterials
7769
NT$6,960.003.0%406.2%NT$1.3tNT$9,322.7186.843.7%0.9%Semiconductors
4417
JP¥3,810.0019.1%26.2%JP¥57.3bJP¥4,500.0038.524.1%0.9%Software
Page 1 of 41